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INTRODUCTION: Multiple studies have suggested blood red blood cell transfusions to be 
individual markers of post-operative outcomes, including infectious complications. This 
study set out to examine statistical relationships between red blood cell transfusions and 
infections following coronary artery bypass grafting surgery,in a retrospective cohort 
design following patients undergoing CABG in Tampere University Hospital in 2014 and 
2015.  
METHODS: Preoperative and intraoperative variables were collected in the study, as well 
as data on intraoperative transfusions. Transfusions of red blood cells were considered an 
ordinal variable, with stratification following number of units of RBCs transfused. Study 
outcome variables included development of post-operative pneumonia, mediastinal 
surgical site infection, or serious nosocomial infection (SNI). Univariate analysis was the 
mainstay of statistical analysis of collected data. Relevant percentages and p-values were 
calculated for comparisons of study variables and outcomes.  
RESULTS: A total of 461 patients undergoing CABG where included in the study. Red 
blood cell transfusions where significantly associated with development of post-operative 
mediastinitis. Totally, 38 patients received 2 units of RBCs, of which mediastinitis 
presented in 4 cases or 10% of cases in the group (p = 0.03). No statistically significant 
correlation was observed in the comparison of RBC transfusions and pneumonia or 
serious nosocomial infection rates. Female sex in patients was significantly associated 
with development of pneumonia (6 cases of pneumonia, covering 7% of total female 
patients, compared to 7 cases of pneumonia, accounting for 2 % of male patients, p = 
0.007). Obesity (BMI > 30 kg/m2) was associated with a decreased rate of pneumonia (0 
pneumonias, or 0% in obese patients, compared to 13 pneumonia patients, representing 
4% of the non-obese group, p = 0,024) and SNI (3 cases, or 2% of patients in the obese 
group, versus 25 cases or 7% in the non-obese group, p = 0,048). 
CONCLUSIONS: Statistical analysis revealed an association between transfusion of 2 red 
blood cell units and mediastinitis post-operation. The study also produced surprising 
results pertaining to development of infections in obese and female patients. A number of 
factors limit the reliability of study results, including modest sample size and restriction of 
analysis to the univariate level. Optimization of intraoperative patient blood management 
should continue to be an object of further studies.  
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1 INTRODUCTION 
 
 
1.1 Blood transfusion in cardiac surgery 
 
Transfusion of blood products remains commonplace in heart surgery. In the United 
States, an estimated 10-20% of all blood transfusions are used in the perioperative care of 
patients undergoing cardiac surgical procedures (1,2). Despite the perceived blood 
product needs of cardiosurgical patients, significant post-operative complications 
associated with transfusion have been highlighted in both evidence, and guidelines 
published by the American College of Cardiology and the European Association of 
Cardiothoracic Surgery. The same guidelines stress that conservative strategies in 
administration of blood products may have both financial and medical benefits to liberal 
transfusion strategies (1,3). Nevertheless, both the complexity of cardiac procedures and 
prevalence of preoperative patient comorbidity pose problems in the management of 
anemic and bleeding patients. In addition to these obstacles, lack of evidence-based 
triggers for transfusion and poorly understood causal mechanisms further confound the 
choice of strategy for the practicing physician (4). This is especially seen in multicenter 
studies which show that variance in individual transfusion practices, on the institutional 
level, has been significant. In lack of concrete understanding, practices in many cases are 
being influenced by both local conventions and individual standards, besides evidence 
(5,6).  
 
1.2 Indications for Red Blood Cell transfusion  
 
The theoretical goal and accepted indication for transfusion of red blood cells (RBCs) is 
the prevention of injury related to inadequate tissue oxygenation (7),  presenting as a 
consequence of significant bleeding or anemia (8). Patients undergoing coronary artery 
bypass grafting (CABG), the most common type of heart operation (9), constitute a group 
of notably heightened risk for these outcomes. Typical baseline characteristics for this 
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population include advanced age, BMI>25 kg/m2, diabetes, chronic obstructive pulmonary 
disease, peripheral vascular disease, prior acute coronary syndromes, and regular use of 
potent anticoagulants (10-12). Not surprisingly, the average incidence of bleeding alone as 
a complication has been observed to be as high as 30 % (13) in CABG patients. In 
particular, a retrospective cohort study found that major bleeding necessitating re-
exploration was associated with 3 times higher mortality rates and significantly longer in-
hospital length of stay following operation, for patients undergoing CABG (14). A 
subsequent study further solidified massive blood loss as a strong, independent risk factor 
for in-hospital mortality, following multivariate analysis (15).  
 
Preoperative anemia, the second important determinant of RBC transfusion (16), defined 
on basis of blood hemoglobin concentration, is an additional factor thought to be 
associated with adverse outcomes in cardiac surgery. An anemic state, preceding 
operation, is common in cardiosurgical patients. This anemia can be either hospital-
acquired, related to coronary angiography preceding surgery, or associated with iron-
deficiency or comorbidities (e.g. chronic renal disease) (17). An independent association 
between preoperative anemia and postoperative morbidity and mortality has been 
recorded in multiple publications and meta-analyses of evidence. Associated outcomes 
include postoperative stroke (18,19), acute kidney failure (AKI) (19-21), infection (21) and 
mortality (21,22).  
 
1.3 Problematics of RBCs 
 
Roughly 50 % of patients undergoing CABG receive allogeneic red blood cell transfusions 
(23). This is largely done for the prevention of the potentially ischemic complications 
described above (24). In some cases indeed, such as hemorrhagic shock, the efficacy of 
allogeneic RBCs in reducing negative outcome has been justified, and transfusion of 
patients with hemoglobin levels of 6 g/dL or less has been called reasonable, in guidelines, 
and potentially life-saving. (25) 
 
On the other hand, the safety of RBC transfusions has lately been a subject of scientific 
scrutiny. A growing body of publications in the last two decades has identified a positive 
and independent correlation between blood product usage and adverse results, following 
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cardiac surgery. Studies have reported transfusions to be linked to a substantially greater 
hazard for post-operative events like infections (26-31) such as pneumonia or 
mediastinitis, ischemic kidney injury (12,26,28,30) and cardiac complications (26,12, 30, 
31), with corresponding influence on long-term patient mortality, in 1- and 5-year cohorts 
following operation (32-34). Adjusted hazard ratios for short term post-operative mortality 
have also consistently indicated at least 50% greater chances of death following 
transfusion in cardiac surgery (12,26,27,30,35), and worsened functional outcome (36). 
What is worse, results following multivariate analysis have also shown transfusions to 
increase the already acknowledged probability for adversity in anemic and bleeding 
patients, in a multiplicative manner on previously observed hazard ratios (37,38). 
 
Attempts at interpretation of these results have presented a long-known 
immunomodulatory response (TRIM) of transfusion recipients to allogeneic blood products, 
as a probable contributor for infectious post-operative events (4,39). Besides scarce 
evidence on immunomodulation’s actual impact on post-operative pathology in non-
immunocompromised individuals, this conception has led to a widespread international 
adoption of pre-storage depletion of white blood cells from RBCs products, with the 
exception of the United States (40). This has been done to ensure that potential yet-to-be-
proven negative effects are prophylactically reduced. RCTs comparing leukoreduced blood 
products to standard issue transfusions, however, have not given conclusive results and 
have only testified to their relative safety and in only some cases, to the reduction of 
infections (41).   
 
In order to respond to the compelling findings surrounding transfusions, surgical and 
anesthesiological guidelines are being adapted to the state of evidence. Focus of patient 
blood management has transitioned to the overall reduction of transfusion requirements, 
and the development of new protocols for the evaluation of this requirement during 
operations (3,42). Such protocols include decision making algorithms based on point-of-
care thromboelastography (TEG) or thromboelastometry (TEM). While these strategies 
have proven effective in the reduction of overall blood transfusions, they have not been 
shown to significantly improve odds for adverse outcome, when compared to conventional 
transfusion strategies (43). The true benefit has thus been a reduction in the considerable 
costs incurred by unnecessary transfusion of blood products (26).  
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Currently both European and North American guidelines agree in the choice of restrictive 
transfusion strategies during perioperative patient management, and the same statements 
recognize the increased risk of transfused patients for complications (3,27). Restrictive 
strategies are usually defined by a set blood hemoglobin concentration threshold, above 
which transfusions are not recommended (typically 8 g/dL) (4). Still, concrete findings have 
not yet been made on their efficacy (44,45).  
 
1.4    Additional questions and study hypothesis 
 
Multiple articles have referenced a progressive relationship between the amount of RBCs 
transfused and adverse outcome (26,27,29,30,34). However, reliable transfusion 
thresholds or evidence-based preferential strategies for intraoperative patient blood 
management in cardiac surgery patients do not yet exist. This fact stands out, as some 
publications have recorded even singe units of RBCs having potentially severe 
associations with postoperative outcomes (38,46). Little consensus exists on what 
threshold of transfusion (if existent) carries heightened risk of complications, while some 
studies have reported 4 or 5 units of RBCs as a potential cutline of transfusion safety for 
some outcomes (33,35). The investigation of a dose-dependent relationship between 
blood products and adverse events following surgery has notable importance, since 
transfusion of 1 -2 U of RBCs is considered low-risk when compared to potential benefit, 
and in some instances has been called “discretionary” (46). 
 
The current study set out to examine red blood cell transfusions in the context of infectious 
outcomes. Recent publications have focused on and exclusively referenced notable 
associations between administration of intraoperative RBCs and pneumonia (47), 
mediastinitis, and/or severe septicaemia (27). Special focus will be taken into the 
examination of a proposed dose-dependent relationship between RBC transfusions and 
infections presenting as post-operative complications. As part of the study, analysis and 
evaluation of pre-operative patient population features will be also factored into the 
development of the results.  
 
 
5 
 
2 METHODS 
 
 
2.1 Systematic review 
 
2.1.1 Purpose and study identification 
 
A systematic review of the current evidence was conducted for the purposes of the study. 
Data extracted from the systematic review was utilized in the design of the retrospective 
cohort study and the evaluation of its results.  
 
Searches were conducted in the following databases: Ovid MEDLINE(R) Epub Ahead of 
Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE 
and Versions(R)”. The default Ovid Technologies, Inc. search engine was used, from a 
computer with access to University of Tampere’s license for scientific publications.  
 
The inclusion criteria for the studies were defined as follows. Only original studies that 
included adult cardiac surgery patients as their main study population were selected. 
Cardiac surgery was defined as either coronary artery bypass or heart valve surgery. 
Selected studies had to have postoperative complications as their main outcome variables. 
The selected studies also had to be in the English language and have transfusion of blood 
products as their main intervention or part of their main interventions. Furthermore, studies 
describing autologous blood transfusion as their main intervention were not included in the 
review, due to difficulty in comparison of their study populations with allogeneic transfusion 
studies’ populations. Other reviews, patient series, case reports, letters and other non-
original studies were excluded from this review, as well as articles which were only 
available in abstracts.  
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2.1.2 Search strategy 
 
The search strategy utilized is presented in detail in Table 1. Searches were structured 
using the “PICO” search strategy template. Patient population (P) was defined with  
search #5 (“Cardiovascular surgical procedures (MeSH)” OR “Coronary Artery Bypass 
(MeSH)” OR “CABG (All fields)” OR “Coronary Artery Bypass (All fields)”). The intervention 
(I) was formulated using non-MeSH and MeSH-terms for “Blood transfusion”, “Platelet 
transfusion”, “Erythrocyte transfusion”, as well as “All fields”-searches for the terms 
“cryoprecipitated plasma”, “blood products” and “frozen plasma” (search #15). 
Complication (C) and outcome (O) were defined by combining search #22 (“complications 
(all fields)” AND “postoperative (all fields)”) with the main expected complication in these 
patient groups (hemorrhage) expressed in MeSH and non-MeSH terms (“hemorrhage (all 
fields)” OR “Hemorrhage (MeSH)” OR “Postoperative Hemorrhage (MeSH)”). The 
combined results for the target outcome were produced with search #23. 
Finally, results for the defined patient population, intervention, and outcome were 
combined with the AND command (search #24). The result was 997 potentially relevant 
articles.   
 
Table 1. Utilized search strategy 
1.   Cardiovascular surgical procedures (MeSH) 13. cryoprecipitated plasma (all fields) 
2. Coronary Artery Bypass (MeSH) 14. frozen plasma (all fields) 
3. CABG (All fields) 
15. 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 
      13 OR 14 
4. Coronary Artery Bypass (All fields) 16. Hemorrhage (MeSH) 
5. 1 OR 2 OR 3 OR 4 17. Hemorrhage (all fields) 
6. Blood transfusion (MeSH) 18. Postoperative Hemorrhage (MeSH) 
7. Blood transfusion (All fields) 19. 16 OR 17 OR 18 
8. Platelet transfusion (MeSH) 20. complications (all fields) 
9. Platelet transfusion (All fields) 21. postoperative (all fields) 
10. Erythrocyte transfusion (MeSH) 22. 20 AND 21 
11. Erythrocyte transfusion (All fields) 23. 19 AND 22 
12. Blood products (all fields) 24. 5 AND 15 AND 23  
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2.1.3 Assessment of results and final study selection 
 
Figure 1  presents the selection process for the 997 articles acquired through the search 
strategy. Screening for duplicates produced 932 relevant publications. Title based 
screening excluded 874 studies from the review, based on previously defined inclusion 
criteria. A total of 58 studies where screened based on text, and following exclusion of 
articles not compliant to the inclusion criteria and removal of studies only available as 
abstracts through the University’s license, a total of 21 articles remained for inclusion in 
the review. References of these publications where also examined, and an additional 8 
acceptable articles where extracted, making for a total of 29 original studies which were 
used for the review of evidence in the introduction (9–16,19–21,25–39,42,46,47). Generic 
commentary of the status quo in clinical practice was supplemented with independently 
indexed references, which account for additional bibliography in this study. 
Figure 1. Flow chart for study selection process 
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2.2 Retrospective Cohort Study 
 
2.2.1 Study materials  
 
The present study set out to retrospectively examine patients undergoing coronary artery 
bybass grafting surgery in Tampere University Hospital in the years 2014 - 2015. The 
collection of patient data for the purposes of the study received approval from the Heart 
Hospital, Tampere University Hospital in 2018.  
 
Patient information and perioperative variables from CABG operations in the years 2014 – 
2015 were manually processed from the University Hospital’s electronic patient information 
database, MD-Uranus (CGI Group Inc. Finland). Intraoperative transfusion records and 
anesthesiological data were retrieved from physical patient records. Patients with 
incomplete medical information on the performed operation were not included in the study. 
Data was initially collected and tabulated into Microsoft Office Excel (Microsoft Corp., 
version 2016), and later imported and further analysed in SPSS Statistics (IBM Corp., 
version 24).  
   
2.2.2 Collection and classification of baseline patient characteristics 
 
Baseline characteristics of study population were collected followingly. Patients were 
stratified with respect to age into two classes, namely patients with 65 or above years of 
age, and patients with less than 65 years of age. Sex was recorded as either male or 
female. Through patient data on height and preoperative weight, patients’ preoperative 
body-mass indeces (BMI)  were calculated and used to classify patients into either obese, 
for a BMI above 30 kg/m2, and non-obese, for a correspondingly lower BMI. Smoking as a 
health habit was recorded as a categorical variable, into classes “Yes”, for an active 
smoker, “No” for a patient that had never smoked, and “Ex-smoker” for a former smoker 
that had quit, based on clinical history taking documented into patient electronic records.  
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Patients’ long term diagnoses were also collected, and treated as dichotomous variabes. 
These included diagnosed arterial hypertension, diabetes mellitus (insulin-dependent or 
not), peripheral arterial disease, chronic obstructive pulmonary disorder (COPD). Patient 
data was also similarly collected on previous stroke history and previously performed 
percutaneous coronary intervention. 
 
Cardiac function was documented in the study as an ordinal variable, based on left 
ventricular ejection fraction percentage, as measured though cardiac ultrasonography by a 
practicing University Hospital cardiologist. Cardiac function was classified as either “≥ 50 
%; Normal”, “30 – 50 %; Compromised” and “≤ 30%; Severe”.  
 
Tampere University Hospital also calculated numerical EuroSCORE II evaluations 
(European System for Cardiac Operative Risk Evaluation) for all patients undergoing 
CABG. The EuroSCORE values for study patients were included in the study, and 
stratified into three ordinal classes, “0 – 2 ”, “2 – 5” and “> 5”.  
 
2.2.3 Classification of perioperative and outcome variables 
 
The urgency of the indication for CABG was documented for the purposes of the present 
study, and categorized as either “Elective” for non-, “Hastened” for CABG occuring within 2 
– 4 days following decision for surgical intervention, and “Emergency” for CABG performed 
within 24 hours of patient presentation to the Hospital’s Emergency Department. 
 
Anesthesiological technique during operation was considered as either “on-pump” or “off-
pump”, pertaining to the usage of mechanical cardiopulmonary bypass or not, respectively.  
 
Intraoperative blood product transfusions were included in the study in the following way. 
Transfusion of red blood cells was considered an ordinal variable, stratified according to 
the number of standard units used during operation. Classes were defined “None”, for no 
transfusion, and “1 Unit”, “2 Units”, “3 Units” and “≥ 4 Units”, on the basis of the number of 
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used units, respectively. Likewise, transfusion of blood platelets was considered in tems of 
standard units transfused, with patient being classified into 3 groups, termed “None”, for no 
platelets transfused, “2 Units” for transfusion of 2 standard units and “> 2 Units” for 
transfusion of platelets exceeding aforementioned amount. Blood products used in 
Tampere University Hospital are procured by the Finnish Red Cross Blood Service, and 
standard units used during operation are defined by the Blood Service. One unit of red 
blood cells is reported as roughly amounting to 300 milliliters of product, while one unit of 
platelets is reported to amount to roughly 250 milliliters of product (48). Usage of blood 
product derivatives, such as Octaplas®, Octaplex®, or Fibrogammin®, were not included 
in the study.  
 
The study’s primary outcomes, namely post-operative infections, were considered  
dichotomous variables, indicating presence or not of the infectious complication. Infections 
considered were bacterial pneumonia, mediastinitis, and serious nosocomial infection. In 
the University Hospital, diagnoses of pneumonia and mediastinitis are made based on the 
combination of clinical and radiographic evidence of localized bacterial infection. A post-
operative complication of septicaemia was considered a serious nosocomial infection, 
when evidence of systemic inflammatory response to infection was observed along with 
evidence of organ failure. Interpretation of aforementioned evidence followed Finnish 
national practice guidelines where applicable, and hospital approved guidelines were 
followed where national guidelines were not applicable.  
 
2.2.4 Statistical analysis of data 
 
Data was analysed in SPSS Statistics version 24. Univariate analysis of study variables 
was the principal method of statistical evaluation. With respect to the classification of 
variables, none were considered continuous. Variables were analysed as categorical, 
ordinal or dichotomous. Dichotomous variables were evaluated in relation to ordinally 
categorized ones by utilizing the Wilcoxon-Mann-Whitney test, whereas testing of 
variables with 3 categories or above with ordinal variables was done with Kruskal Wallis 
tests. Statistical comparison of dichotomous variables with other dichotomous varibles was 
made with conventional chi-squared tests where at least 5 instances existed of each 
variable. In cases where this term was not fulfilled, Fisher’s exact test was used. This 
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same procedure was also used when comparing variables considered non-ordinal and 
having three categories or above with other variables considered non-ordinal. For the 
purposes of the study, p-values from each statistical test were tabulated along with 
rounded percentages for the representative instances of the study variables’ statistics.  
 
 
3 RESULTS 
 
 
3.1 Descriptive statistics of study population 
 
In total, characteristics and perioperative information from 461 patients were included in 
the study. A total of 41 patients were excluded from the study, due to incomplete or 
missing records of hospitalization and treatment. Baseline characteristics of patients 
included in the study are presented in Table 2.  Patients of age equal to or above 65 years 
and male sex were characteristically in majority of the study population, totalling 301 (65 
%) and 378 (82 %) of patients, respectively. Comorbidity included hypertension in 73 %, 
diabetes mellitus in 32%, peripheral arterial disease in 9 %, and chronic obstructive lung 
disease in 10 % of CABG patients. Of all patients, 28 % were considered obese, and 17 % 
were active smokers while awaiting operation, while non-smokers represented 52 % of the 
study population, and ex-smokers 31 %. Patients that had suffered stroke in their history 
accounted for 9 %, while 3 % of patients undergoing CABG had previously been subjects 
of PCI. 70 % of patients were evaluated as having normal cardiac ejection fraction, 27 % 
had compromised left ventricular ejection fraction, while 3 % had severe impairment of 
cardiac function, with an LVEF of below 30 %. Individuals with calculated EuroSCOREs 
below 2 accounted for 58 % of the population, while 28 % had a calculated EuroSCORE 
between 2 and 5, and 14 % scored above 5 in EuroSCORE. Of all operations, 15 % 
represented surgical intervention in the emergency setting, while 34 % of operations were 
considered hastened. 51 % were elective and non-emergency. 5 % of all operations were 
performed without cardiopulmonary bypass.  
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Intraoperative transfusions occurred as follows. 93 % of patients received no platelet 
transfusions, while 6 % received 2 Units of platelets, leaving 1 % of patients as having 
received above 2 Units of platelets. In terms of red blood cells, 84 % of patients were not 
deemed in need of intraoperative transfusion, 2 % of patients were transfused with 1 Unit 
of red blood cells. Patients that received 2 Units of RBCs accounted for the majority of 
transfusions at 8 %, while 2 % received 3 Units and 3 % received 4 Units or above of 
RBCs, respectively.    
 
                       
 
     
 
 
Table 2. Baseline characteristics of study population. (Abbreviations:, PAD = Peripheral 
Arterial Disease, COPD = chronic obstructive pulmonary disorder, PCI = percutaneous 
coronary intervention, CABG = coronary artery bypass grafting) 
Variables Patients (%)             
(n=461) 
Age   
≥ 65 years 301 (65) 
< 65 years 160 (35) 
Sex   
Male 378 (82) 
Female 83 (18) 
Hypertension 338 (73) 
Diabetes Mellitus 147 (32) 
PAD 43 (9) 
Obesity 127 (28) 
Smoking   
Ex-smoker 144 (31) 
No  240 (52) 
Yes 77 (17) 
COPD 46 (10) 
Stroke history 41 (9) 
Previous PCI 15 (3) 
Ejection Fraction (%)   
   ≥ 50(Normal) 322 (70) 
30 – 50 (Compromised) 125 (27) 
               ≤ 30 (Severe) 14 (3)  
EuroSCORE   
0-2 269 (58) 
2-5 127 (28) 
>5 65 (14) 
Variables Patients (%)             
(n=461) 
Indication for CABG   
Elective 237 (51) 
Hasty 156 (34) 
Emergency 68 (15) 
Technique (off-pump) 25 (5)  
  
Transfusion   
Thrombocytes   
> 2 Units 4 (1) 
2 Units 30 (6) 
None 427 (93) 
Red Blood Cells   
1 Unit 9 (2) 
2 Units 38 (8) 
3 Units 9 (2) 
≥ 4 Units 16 (3) 
None 389 (84) 
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3.2 Results of statistical analysis 
 
3.2.1 Effect of baseline characteristics on transfusion 
 
Results of comparative statistical evaluation of baseline characteristics to intraoperative 
transfusions are presented in table 3. Relevamt percentages are displayed in respect to 
row variables. Significant associations where noted between preoperative left ventricular 
ejection fraction (p < 0.001), previous percutaneous coronary intervention (p = 0,044), 
urgency of indication for surgery (p = 0,049) and red blood cell transfusions. Within 
patients with compromised LVEF, 22% were given transfusion of red blood cells, while 
severely lowered LVEF was associated with transfusion in 43 % of patients, compared to 
transfusions occuring only in 12 % of patients with normal cardiac function. Patients with 
previous percutaneous intervention in history were subject to transfusions in 33 % of 
cases, compared to 15 % in the group with no previous PCI. Patients operated with an 
elective indication for intervention were administered RBCs in 16 % of cases, while 
transfusions in hastened operations were represented in 19 % of patients. Only 6 % of 
patients undergoing emergency CABG were given red blood cell transfusions. 
Transfusions of thrombocytes where also significantly associated with RBC transfusions (p 
< 0.001), as is to be expected in the management protocols of intraoperative bleeding.  
 
Contrarywise, no significant correlation was observed between other descriptive patient 
variables, such as age, sex, hypertension, obesity, tobacco smoking, COPD, peripheral 
arterial disease, diabetes mellitus or EuroSCORE.  
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Variable 
Patients (%)   
RBC Transfusion   
0 1U 2U 3U ≥4U p-value 
Age        
<65 years 136 (85) 4 (3) 15 (9) 3 (2) 2 (1)   
≥65 years 253 (84) 5 (2) 23 (8) 6 (2) 14 (5) 0,666 
Gender        
Female 72 (87) 0 (0) 3 (4) 2 (2) 6 (7)   
Male 317 (84) 9 (2) 35 (9) 7 (2) 10 (3) 0,689 
Ejection 
fraction        
≥ 50 % 283 (88) 5 (2) 23 (7) 6 (2) 5 (2)   
30‒50 % 98 (78) 3 (2) 14 (11) 2 (2) 8 (6)   
≤ 30 % 8 (57) 1 (7) 1 (7) 1 (7) 3 (21) <0.001 
Euroscore        
0‒2 223 (83) 8 (3) 22 (8) 5 (2) 11 (4)   
2‒5 105 (83) 1 (1) 12 (9) 4 (3) 5 (4)   
>5 61 (94) 0 (0) 4 (6) 0 (0) 0 (0) 0,069 
Obesity        
No 279 (84) 9 (3) 27 (8) 8 (2) 11 (3)   
Yes 110 (87) 0 (0) 11 (9) 1 (1) 5 (4) 0,468 
Smoker        
No 197 (82) 5 (2) 23 (10) 5 (2) 10 (4)   
Yes 66 (86) 1 (1) 4 (5) 3 (4) 3 (4)   
Ex 126 (88) 3 (2) 11 (8) 1 (1) 3 (2) 0,324 
Stroke history        
No 350 (83) 8 (2) 38 (9) 8 (2) 16 (4)   
Yes 39 (95) 1 (2) 0 (0) 1 (2) 0 (0) 0,045 
Hypertension        
No 108 (88) 2 (2) 8 (7) 2 (2) 3 (2)   
Yes 281 (83) 7 (2) 30 (9) 7 (2) 13 (4) 0,219 
COPD        
No 350 (84) 8 (2) 36 (9) 8 (2) 13 (3)   
yes 39 (85) 1 (2) 2 (4) 1 (2) 3 (7) 0,986 
PAD        
No 350 (84) 8 (2) 36 (9) 8 (2) 16 (4)   
Yes 39 (91) 1 (2) 2 (5) 1 (2) 0 (0) 0,21 
DM        
No 264 (84) 5 (2) 27 (9) 7 (2) 11 (4)   
Yes 125 (85) 4 (3) 11 (7) 2 (1) 5 (3) 0,754 
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Variable 
Patients (%)   
RBC Transfusion   
0 1U 2U 3U ≥ 4U p-value 
Previous PCI        
No 379 (85) 8 (2) 37 (8) 8 (2) 14 (3)   
Yes 10 (67) 1 (7) 1 (7) 1 (7) 2 (13) 0,044 
Indication         
Elective 198 (84) 5 (2) 17 (7) 6 (3) 11 (5)   
Hastened 127 (81) 3 (2) 19 (12) 3 (2) 4 (3)   
Emergency 64 (94) 1 (1) 2 (3) 0 (0) 1 (1) 0,049 
Technique        
Off-Pump 23 (92) 0 (0) 1 (4) 0 (0) 1 (4)   
On-Pump 366 (84) 9 (2) 37 (8) 9 (2) 15 (3) 0,306 
Blood platelets       
No transfusion 372 (87) 8 (2) 33 (8) 8 (2) 6 (1)   
2U 16 (53) 0 (0) 5 (17) 0 (0) 9 (30)   
>2U 1 (25) 1 (25) 0 (0) 1 (25) 1 (25) <0.001 
 
Table 3. Analysis of baseline characteristics to red blood cell transfusions (Abbreviations: 
RBC = Red Blood Cell, PAD = Peripheral Arterial Disease, COPD = chronic obstructive 
pulmonary disorder, DM = Diabetes Mellitus, PCI = percutaneous coronary intervention, 
CABG = coronary artery bypass grafting). Relevant p-values, describing probability of 
documented results for null hypothesis of correlation between row variables and red blood 
cell transfusions, are displayed in the right end of the table. 
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3.2.2 Infectious outcomes 
 
Results of statistical analysis with respect to post-operative infections as outcomes, in 
relation to other study variables, are presented in Table 4. Relevant percentages are 
displayed in respect to row variables. Female sex was significantly associated with 
development of pneumonia, with 7 % of female individuals being diagnosed with 
pulmonary infection post operation, compared to 2 % in the male group (p = 0,007). No 
similar associations where found in the development of mediastinitis (p = 0,665) or serious 
nosocomial infection (p = 0,983). A statistically significant correlation between obesity and 
incidence of post-operative pneumonia and development of serious nosocomial infection 
was also observed in the study population. Out of 127 patients considered obese, based 
on BMI calculations, 0 % were cited as acquiring pneumonia, when compared to the non-
obese patient group, where pneumonia developed in 4 % of cases (p = 0,024). 
Additionally, 2 % or 3 patients belonging to the obese group developed SNI, compared to 
the non-obese group where serious nosocomial infection was observed in 7 % of cases, or 
25 patients (p = 0,048). 
 
Transfusions of platelet products where significantly associated with patients acquiring 
post operational pneumonia. In the group receiving more than 2 units of platelets, 1 patient 
(25 %) developed pneumonia, while in the group receiving 2 units of platelets, 2 patients (7 
%) were diagnosed with pneumonia. This was statistically significant (p = 0,01) when 
compared to the group receiving no platelet transfusions, in which 2 % or 10 patients 
developed pneumonia. No similar associations where seen in the cases of mediastinitis (p 
= 0,823) or SNI (p = 0,871). In patients that received no red blood cell transfusions, 
mediastinitis developed in 1,3 % of cases (5 patients), while mediastinitis was not 
observed in any patients receiving 1 unit, 3 units, or 4 units and above of red blood cells. 
Patients transfused with 2 units of RBCs developed mediastinitis in 10,5 % of cases, 
totaling 4 patients. In Fisher’s exact test, this proved to be a statistically significant 
correlation between RBC transfusions and development of mediastinitis (p = 0,03). No 
statistical significance was observed between red blood cell transfusions and development 
pneumonia (p = 0,193) or SNI (p = 0,526). 
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Patients (%) 
Pneumonia  Mediastinitis  SNI 
No Yes 
p-
value 
  Νο Yes 
p-
value 
  No yes p-value 
Age             
<65 years 155 (97) 5 (3)   156 (97,5) 4 (2,5)   149 (93) 11 (7)   
≥65 years 293 (97) 8 (3) 0,773  295 (98,3) 5 (1,7) 0,725  284 (94) 17 (6) 0,599 
Gender             
Female 77 (93) 6 (7)   80 (97,6) 2 (2,4)   78 (94) 5 (6)   
Male 371 (98) 7 (2) 0,007  371 (98,1) 7 (1,9) 0,665  355 (94) 23 (6) 0,983 
Ejection fraction            
≥50 % 315 (98) 7 (2)   315 (97,8) 7 (2,2)   306 (95) 16 (5)   
30-50 % 120 (96) 5 (4)   122 (98,4) 2 (1,6)   114 (91) 11 (9)   
≤ 30 % 13 (93) 1 (7) 0,353  14 (100) 0 (0) 0,805  13 (93) 1 (7) 0,31 
Euroscore             
0-2 261 (97) 8 (3)   262 (97,8) 6 (2,2)   258 (96) 11 (4)   
2-5 123 (97) 4 (3)   127 (100) 0 (0)   115 (91) 12 (9)   
>5 64 (98) 1 (2) 0,793  62 (95,4) 3 (4,6) 0,08  60 (92) 5 (8) 0,096 
Obesity             
No 321 (96) 13 (4)   327 (98,2) 6 (1,8)   309 (93) 25 (7)   
Yes 127 (100) 0 (0) 0,024  124 (97,6) 3 (2,4) 0,712  124 (98) 3 (2) 0,048 
Smoker             
No 237 (99) 3 (1)   237 (98,8) 3 (1,3)   227 (95) 13 (5)   
Yes 73 (95) 4 (5)   76 (98,7) 1 (1,3)   73 (95) 4 (5)   
Ex 138 (96) 6 (4) 0,096  138 (96,5) 5 (3,5) 0,277  133 (92) 11 (8) 0,636 
Stroke history             
No 408 (97) 12 (3)   410 (97,9) 9 (2,1)   395 (94) 25 (6)   
Yes 40 (98) 1 (2) 1  41 (100) 0 (0) 1  38 (93) 3 (7) 0,729 
Hypertension             
No 120 (98) 3 (2)   121 (98,4) 2 (1,6)   117 (95) 6 (5)   
Yes 328 (97) 10 (3) 1  330 (97,9) 7 (2,1) 1  316 (93) 22 (7) 0,661 
COPD             
No 404 (97) 11 (3)   406 (98,1) 8 (1,9)   387 (93) 28 (7)   
yes 44 (96) 2 (4) 0,379  45 (97,8) 1 (2,2) 1  46 (100) 0 (0) 0,097 
ASO             
No 406 (97) 12 (3)   408 (97,8) 9 (2,2)   392 (94) 26 (6)   
Yes 42 (98) 1 (2) 1  43 (100) 0 (0) 1  41 (95) 2 (5) 1 
 
Diabetes Mellitus             
No 306 (97) 8 (3)   307 (97,8) 7 (2,2)   298 (95) 16 (5)   
Yes 142 (97) 5 (3) 0,606  144 (98,6) 2 (1,4) 0,726  135 (92) 12 (8) 0,199 
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Variable 
Patients (%) 
Pneumonia  Mediastinitis  SNI 
No Yes 
p-
value 
  Νο Yes 
p-
value 
  No yes p-value 
Previous PCI             
No 433 (97) 13 (3)   437 (98,2) 8 (1,8)   418 (94) 28 (6)   
Yes 15 (100) 0 (0) 1  14 (93,3) 1 (6,7) 0,26  15 (100) 0 (0) 0,614 
Indication              
Elective 228 (96) 9 (4)   234 (99,2) 2 (0,8)   224 (95) 13 (5)   
Hastened 152 (97) 4 (3)   150 (96,2) 6 (3,8)   149 (96) 7 (4)   
Emergency 68 (100) 0 (0) 0,242  67 (98,5) 1 (1,5) 0,105  60 (88) 8 (12) 0,096 
Technique             
Off-Pump 25 (100) 0 (0)   25 (100) 0 (0)   21 (84) 4 (16)   
On-Pump 423 (97) 13 (3) 1  426 (97,9) 9 (2,1) 1  412 (94) 24 (6) 0,057 
Thrombocytes             
No transfusion 417 (98) 10 (2)   418 (98,1) 8 (1,9)   401 (94) 26 (6)   
2U 28 (93) 2 (7)   29 (96,7) 1 (3,3)   28 (93) 2 (7)   
>2U 3 (75) 1 (25) 0,01  4 (100) 0 (0) 0,823  4 (100) 0 (0) 0,871 
Transfusion RBCs            
No transfusion 379 (97) 10 (3)   384 (98,7) 5 (1,3)   364 (94) 25 (6)   
1 RBC 9 (100) 0 (0)   9 (100) 0 (0)   9 (100) 0 (0)   
2 RBC 37 (97) 1 (3)   34 (89,5) 4 (10,5)   37 (97) 1 (3)   
3 RBC 9 (100) 0 (0)   9 (100) 0 (0)   9 (100) 0 (0)   
≥4  RBC 14 (88) 2 (13) 0,193   16 (100) 0 (0) 0,03   14 (88) 2 (13) 0,526 
 
Table 4. Analysis of infectious outcomes based on baseline characteristics and transfusions 
(Abbreviations: RBC = Red Blood Cell, PAD = Peripheral Arterial Disease, COPD = chronic 
obstructive pulmonary disorder, DM = Diabetes Mellitus, PCI = percutaneous coronary 
intervention, CABG = coronary artery bypass grafting). Relevant p-values, describing 
probability of documented results for null hypothesis of correlation between row and column 
variables, are displayed in the column to the right of the column variable.  
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4 DISCUSSION 
 
 
This study set out to examine rates of post-operative infectious complications, and 
compare them to rates of intraoperative blood product transfusions. Results suggested a 
strong association between transfusions of red blood cells in the operating room and 
development of mediastinal surgical site infections. However, mediastinal infections 
occurred only in the patient group receiving 2 units of red blood cells, which included a 
total of 38 patients, while similar outcomes where not observed in other patient groups 
receiving a differing number of red blood cells. Furthermore, no significant associations 
where observed in the development of pneumonia or serious nosocomial infections. These 
considerations pose a challenge in the interpretation of the role of transfusions as an 
independent marker of infectious complications. While 2 units of RBCs where statistically 
associated in a significant way with mediastinal infection, patient numbers in groups 
receiving a different unit quantity of RBCs were modest. In total, only 9 patients received 1 
unit of red blood cells and 9 patients were transfused with 3 units. Transfusion of 4 RBC 
units or above was represented by only 16 patients in the study. Therefore, it is considered 
vital by the study author to highlight the study population limitations in the overall 
distribution of patient cases across different numbers of RBC units transfused in the 
operating room. In conclusion, while study results showcased an association between 
RBC transfusion and post-operative mediastinitis following CABG, clinical implications for 
a preventive cut-off value of RBC units transfused are severely limited by disproportionate 
patient representation in the study setting.  
 
Overall study results do not fall in line with results from publications suggesting dose-
dependent correlations between transfusions and infectious outcomes (27,47). Other 
studies have challenged this interpretation and argued that based on their analytic results, 
frequency of red blood cell transfusions could be serving more as a predictor of overall 
patient disease severity and thus increased risk for unfavorable outcome, and less so as 
an independent marker of complications (49). These views would primarily be in support of 
the 2017 consensus of the European Academy of Cardiothoracic Surgeons and 
Association of Cardiothoracic Anesthesiologists, which concluded that current evidence 
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comparing outcomes in restrictive and liberal transfusion strategies, has not showcased 
significant reduction in adverse outcomes through restrictive transfusion strategies (3).  
 
In the broader scope of the study, a BMI of 30 kg/m2 or above in patients was significantly 
associated with decreased rates of infectious outcomes. It may be noted that this directly 
contradicts results showcasing increased coincidence of infectious outcomes in obese 
patients, produced in other relevant publications (27,47). Further study may be indicated 
for the exploration of this analytic result. Alternatively, it may be argued that the relatively 
lower percentage of obese patients in the study population (28%) could be acting as a 
confounding element in the overall presentation of infectious complications in the study.  
 
Critical evaluation of the results must also be placed in the context of limitations of the 
study. Specific indications for transfusions performed were not available for consideration 
in the study variables. Furthermore, transfusions performed post-operatively in the 
Intensive Care Unit of the Hospital could not be included for analysis due to technical 
limitations of the study. Similarly, variance in surgical technique is not possible to evaluate 
through electronical patient records. Modesty in the total population of patients included in 
the study is also to be considered as a factor limiting the broader applicability of study 
results. Study methods were also limited to only univariate analysis of data.  
 
Understanding of causal mechanisms in post-operative outcomes is challenging to 
elucidate, given the extended multimorbid profile of cardiac surgery patients. 
Heterogeneity in both surgical technique and anesthesiologic management across 
institutions (12), all contribute to the difficulty in isolating the individual contributions of 
variables, such as transfusion, to outcomes (47). Nevertheless, international focus on the 
suspected effect of allogeneic red blood cells on surgical outcomes has still driven the 
development of progress in optimization of intraoperative patient blood management. 
Specifically, novel methods for evaluation of transfusion requirements during anesthesia, 
through thromboelastometry and thromboelastography, for example, allow for future 
prospects of reduced transfusion rates during surgery. These would in turn promise a 
more cost-effective anesthesiological management of cardiothoracic surgery patients in 
the future, as well as tighter scrutiny on intraoperative transfusion practices. Further 
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research is thus indicated in the examination of the use of blood products during 
cardiothoracic surgery.  
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